InvestorNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care
May 15, 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet demands as cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide. “Cardio Diagnostics is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic […]
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention
May 15, 2026
Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights the urgent need for more effective tools that can […]
InvestorNewsBreaks – AI Meets Multi-Omics: Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Earlier, More Precise Cardiac Insights
May 6, 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. “Cardio Diagnostics Holdings is focused on addressing this need by developing advanced solutions that […]
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights
May 1, 2026
Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource demands. Cardio Diagnostics Holdings (NASDAQ: CDIO) is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized […]
InvestorNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Precision Cardiology with Multi-Omic AI Platform
April 30, 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. The company is “developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk […]
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management
April 27, 2026
Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple […]
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health
April 24, 2026
Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments […]
InvestorNewsBreaks – Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’
April 17, 2026
Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the […]
InvestorNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Engages IBN to Support Corporate Communications Strategy
April 8, 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy as it advances blood-based solutions for the prevention and detection of cardiovascular disease. The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to […]
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’
March 31, 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators. At the core of its […]
InvestorNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Schedules Investor Conference Call for Feb. 19, 2026
February 19, 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will host an investor conference call on Feb. 19, 2026, at 3 p.m. Central Time to provide an overview of its precision molecular approach to cardiovascular disease prevention and early detection. The call will include updates on the company commercially available tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), as well as discussion of recent clinical data, […]
Lavish Entertainment, Inc. Expands Presence in Event Production Industry Through the Acquisition of ABI Create
April 11, 2024
LAS VEGAS, April 11, 2024 (GLOBE NEWSWIRE) — via IBN — Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce that Lavish Entertainment (or “Lavish”), a wholly owned subsidiary of GTV, has completed a full acquisition of ABI Create (or “ABI”), a premier event management and production firm. Founded […]